(Q22241416)

Dimensions Publication ID

Dimensions

1000389188

7 February 2023

Preethi G.K. Venkatesh

series ordinal

2

author given names

Preethi G. K.

author last names

Venkatesh

1 reference

Dimensions Publication ID

Dimensions

1000389188

7 February 2023

Udayakumar Navaneethan

series ordinal

3

author given names

Udayakumar

author last names

Navaneethan

1 reference

Dimensions Publication ID

Dimensions

1000389188

The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study

7 February 2023

language of work or name

English

0 references

publication date

December 2012

0 references

published in

Drugs

0 references

volume

72

0 references

issue

18

0 references

page(s)

2333-2349

0 references

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Management of extraintestinal manifestations and other complications of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Serum autoantibodies, ulcerative colitis and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Clinical patterns of familial inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Genetic markers may predict disease behavior in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Association of primary sclerosing cholangitis with HLA-B8.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Thoracic manifestations of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Bone, inflammation, and inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Crohn's disease associated with arthritis: a possible role for cross-reactivity between gut pathogenesis of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Muscoloskeletal manifestations in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Combining information obtained from magnetic resonance imaging and conventional radiographs to detect sacroiliitis in patients with recent onset inflammatory back pain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

THE EXTRA-INTESTINAL COMPLICATIONS OF CROHNʼS DISEASE AND ULCERATIVE COLITIS: A STUDY OF 700 PATIENTS

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Topical tacrolimus therapy for pyoderma gangrenosum

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Crohn's disease associated with Sweet's syndrome and Sjögren's syndrome treated with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Rare extraintestinal manifestations of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Ocular manifestations of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

The etiology of steroid cataract

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Primary Sclerosing Cholangitis, Inflammatory Bowel Disease, and Colon Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Extraintestinal manifestations in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Hepatic and extrahepatic malignancies in primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Duration and severity of primary sclerosing cholangitis is not associated with risk of neoplastic changes in the colon in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Diagnosis and management of primary sclerosing cholangitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Hepatitis B and C virus infection in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Use of infliximab in particular clinical settings: management based on current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Inflammatory bowel disease: complications and extraintestinal manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Pulmonary involvement in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

A case-control study of bronchial asthma associated with ulcerative colitis: role of airway microvascular permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Risk factors for low bone mass in patients with ulcerative colitis following ileal pouch-anal anastomosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Renal manifestations and complications of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Risk factors for developing renal stones in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Peripheral neuropathy and neurological disorders in an unselected Brazilian population-based cohort of IBD patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Peripheral neuropathy in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Increased risk for demyelinating diseases in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Cyclosporine neurotoxicity: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11638120-000000000-00000

Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology

21 January 2018

1 reference

12 December 2020

Skin manifestations of inflammatory bowel disease

1 reference

12 December 2020

Extracolonic diagnoses in ulcerative colitis: an epidemiological study.

1 reference

12 December 2020

Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab

1 reference

12 December 2020

The effect of infliximab on extraintestinal manifestations of Crohn's disease

1 reference

12 December 2020

Renal and urologic complications of inflammatory bowel disease

1 reference

12 December 2020

Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center

1 reference

12 December 2020

Extraintestinal manifestations of inflammatory bowel disease

1 reference

12 December 2020

Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics

1 reference

12 December 2020

The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study

1 reference

12 December 2020

Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation

1 reference

12 December 2020

Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998

1 reference

12 December 2020

Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease

1 reference

12 December 2020

Sweet's syndrome: a clinicopathologic review of twenty-nine cases

1 reference

12 December 2020

The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study

1 reference

12 December 2020

Variant forms of cholestatic diseases involving small bile ducts in adults

1 reference

12 December 2020

Risk of arterial thrombotic events in inflammatory bowel disease

1 reference

12 December 2020

Influence of ileal pouch anal anastomosis on bone loss in ulcerative colitis patients

1 reference

12 December 2020

The lung in inflammatory bowel disease

1 reference

12 December 2020

Sarcoidosis and inflammatory bowel disease

1 reference

12 December 2020

High frequency of silent inflammatory bowel disease in spondylarthropathy

1 reference

12 December 2020

Primary sclerosing cholangitis

1 reference

12 December 2020

Pyoderma gangrenosum complicating ulcerative colitis: successful treatment with methylprednisolone pulse therapy and dapsone.

1 reference

12 December 2020

Extraintestinal manifestations and complications in inflammatory bowel diseases

1 reference

12 December 2020

[Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn's disease and ulcerative colitis]

1 reference

12 December 2020

1 reference

12 December 2020

Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines' criteria

1 reference

12 December 2020

Ocular manifestations of inflammatory bowel disease

1 reference

12 December 2020

Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease

1 reference

12 December 2020

Extraintestinal manifestations of inflammatory bowel disease

1 reference

12 December 2020

Survival and cause-specific mortality in inflammatory bowel disease: a population-based cohort study

1 reference

12 December 2020

Inflammatory bowel disease and the lung: is there a link between surgery and bronchiectasis?

1 reference

12 December 2020

Extraintestinal manifestations of inflammatory bowel disease

1 reference

12 December 2020

Bone density improves with disease remission in patients with inflammatory bowel disease

1 reference

12 December 2020

Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study

1 reference

12 December 2020

Peripheral neuropathy in inflammatory bowel disease patients: a prospective cohort study

1 reference

12 December 2020

Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients

1 reference

12 December 2020

The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease

1 reference

12 December 2020

Extraintestinal manifestations of inflammatory bowel disease

1 reference

12 December 2020